FDA Wants Your Take on Patient Drug Meeting Impacts
Published Date: 5/1/2026
Notice
Summary
The FDA wants to hear from patients, advocates, and drug developers about how past patient-focused drug meetings have helped shape medicine and research. They’ve opened a public comment period until June 30, 2026, to collect stories and ideas that could improve future drug development. This is a great chance for anyone involved in healthcare to share their experience and influence how new treatments are made—no cost to participate, just your voice!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
FDA opens PFDD public docket
The FDA has created a public docket (Docket No. FDA-2026-N-3947) to collect examples of how past patient-focused drug development (PFDD) meetings affected community engagement, research priorities, advocacy strategies, medical product development programs, and clinical practice. Patients, caregivers, family members, patient advocates, medical product developers, healthcare providers, and academic researchers are invited to submit examples and stories to help inform future drug development and research.
Comment deadline and confidentiality rules
Comments must be submitted by June 30, 2026 (electronic submissions accepted via https://www.regulations.gov until 11:59 p.m. Eastern Time that day, or written/paper submissions received by that date at Dockets Management Staff, FDA, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852). Comments posted to the docket will be publicly viewable unless submitted as a confidential written/paper submission; confidential submissions require two copies (one marked confidential and one redacted copy for public posting).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13492 — Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has confirmed that vasopressin in sodium chloride (0.9%, injection) wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can now get approved if they meet all the rules, helping patients and healthcare providers get more options. No changes in price or availability are expected right now, but more generics could be coming soon!
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2026-08523 — Formations of, Acquisitions by, and Mergers of Bank Holding Companies
Some companies want to become bank holding companies or buy banks, and the Federal Reserve is checking their applications. If you have thoughts, you can send comments by June 1, 2026. This affects banks in South Dakota, Nebraska, and Texas, and could shake up who controls these banks soon.
Next: 2026-08525 — Agency Information Collection Extension
The Department of Energy is extending its loan application form for advanced vehicle tech for three more years. This affects companies applying for these special loans and keeps the process going without extra costs or changes. If you want to share your thoughts, make sure to comment by June 1, 2026!